(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and continued growth in US sales of its iron deficiency treatment ACCRUFeR.
The AIM-traded commercial-stage pharmaceutical company said unaudited group net revenue rose to $18m in the three months...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE